# A Phase 2 Study With CC-220 in Skin Sarcoidosis

> **NCT02192489** · PHASE2 · WITHDRAWN · sponsor: **Celgene**

## Conditions studied

- Sarcoidosis

## Interventions

- **DRUG:** CC-220 0.3 mg Daily
- **DRUG:** CC-220 0.6mg Daily
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02192489
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-11-01
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192489, "A Phase 2 Study With CC-220 in Skin Sarcoidosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02192489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*